Novartis Settles Foreign Bribery Charges With US Government
The company agreed to pay $233.9m to the US Department of Justice and $112m to the Securities and Exchange Commission to settle foreign bribery charges tied to South Korea, Vietnam and Greece.
You may also be interested in...
With the eye-care business set for its own stock exchange listings next month and the future of Sandoz the subject of much discussion, Novartis' plan to be a pure play pharma firm moves ever closer.
Sanofi agrees to pay $25.2m to resolve charges its Kazakhstan and Middle East subsidiaries paid bribes to win business; last pharma settlements were in 2016.
Novartis' top lawyer is taking responsibility for the controversial contract with Essential Consultants and stepping down, amid pledges by the company to polish its tarnished image.